WO2010028130A3 - Composés antidépresseurs - Google Patents

Composés antidépresseurs Download PDF

Info

Publication number
WO2010028130A3
WO2010028130A3 PCT/US2009/055865 US2009055865W WO2010028130A3 WO 2010028130 A3 WO2010028130 A3 WO 2010028130A3 US 2009055865 W US2009055865 W US 2009055865W WO 2010028130 A3 WO2010028130 A3 WO 2010028130A3
Authority
WO
WIPO (PCT)
Prior art keywords
antidepressant compounds
compounds
antidepressant
desvenlafaxine
treatment
Prior art date
Application number
PCT/US2009/055865
Other languages
English (en)
Other versions
WO2010028130A2 (fr
Inventor
Roger Tung
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2010028130A2 publication Critical patent/WO2010028130A2/fr
Publication of WO2010028130A3 publication Critical patent/WO2010028130A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des formes deutérées de desvenlafaxine et sur l'utilisation de tels composés dans une composition pharmaceutique et pour le traitement de troubles psychologiques.
PCT/US2009/055865 2008-09-03 2009-09-03 Composés antidépresseurs WO2010028130A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9404508P 2008-09-03 2008-09-03
US61/094,045 2008-09-03

Publications (2)

Publication Number Publication Date
WO2010028130A2 WO2010028130A2 (fr) 2010-03-11
WO2010028130A3 true WO2010028130A3 (fr) 2010-06-10

Family

ID=41797846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/055865 WO2010028130A2 (fr) 2008-09-03 2009-09-03 Composés antidépresseurs

Country Status (1)

Country Link
WO (1) WO2010028130A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027865T2 (en) 2005-12-01 2016-11-28 Auspex Pharmaceuticals Inc Substituted phenyl ethylamines with serotonergic and / or norepinephrine activity
EP3103790B1 (fr) 2007-03-15 2018-05-09 Auspex Pharmaceuticals, Inc. Phénétylamine substituée ayant une activité sérotoninergique et/ou norépinéphrinergique
CN104326923B (zh) * 2014-09-05 2016-02-10 南京华威医药科技开发有限公司 一种琥珀酸去甲文拉法辛的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030537A1 (fr) * 2005-09-07 2007-03-15 Wyeth Formulations topiques contenant un o-desméthylvenlafaxine (odv) ou ses sels
US20070293480A1 (en) * 2006-06-16 2007-12-20 Theracos, Inc. Treating psychological conditions using muscarinic receptor m1 antagonists
WO2008140859A1 (fr) * 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Phénéthylamines substituées à action sérotoninergique et/ou norépinéphrinergique
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030537A1 (fr) * 2005-09-07 2007-03-15 Wyeth Formulations topiques contenant un o-desméthylvenlafaxine (odv) ou ses sels
US20070293480A1 (en) * 2006-06-16 2007-12-20 Theracos, Inc. Treating psychological conditions using muscarinic receptor m1 antagonists
WO2008140859A1 (fr) * 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Phénéthylamines substituées à action sérotoninergique et/ou norépinéphrinergique
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine

Also Published As

Publication number Publication date
WO2010028130A2 (fr) 2010-03-11

Similar Documents

Publication Publication Date Title
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
WO2012075383A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
WO2012174487A8 (fr) Inhibiteurs à bromodomaine et leurs utilisations
WO2012151512A3 (fr) Inhibiteurs de bromodomaines et leurs utilisations
EP2120580A4 (fr) Compositions et procédés de traitement de troubles métaboliques
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
EP2217238A4 (fr) Procédés et compositions pour le traitement de maladies protéinuriques
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
WO2010028130A3 (fr) Composés antidépresseurs
WO2008130319A3 (fr) Nouveaux composés 805
WO2008094054A3 (fr) Composés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812206

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09812206

Country of ref document: EP

Kind code of ref document: A2